Stat3 inhibition in neural lineage cells

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Signal transducer and activator of transcription 3 (Stat3) deregulation is implicated in neurological disorders like Alzheimer's disease (AD) and glioblastoma multiforme (GBM).
• GBM often exhibits constitutive Stat3 activation, making it a target for chemotherapy.
• Stat3 inhibitors may pose risks to non-dividing neurons in the central nervous system.

Purpose of the Study:

• To investigate the cellular responses of neural lineage cells to Stat3 inhibitors.
• To determine the effective concentrations of Stat3 inhibitors on neuronal and glial cells, including cancer cell lines.

Main Methods:

• Tested five human and mouse cancer cell lines (neuroblastoma and glioblastoma) with various Stat3 inhibitors.
• Utilized Stat3 knockdown and dominant-negative Stat3 expression.
• Examined the effect of familial AD-related mutant amyloid precursor protein expression.
• Assessed responses in primary neurons and astrocytes.

Main Results:

• Stattic, FLLL31, and resveratrol potently suppressed P-Stat3 and cell viability across all tested cell lines.
• Stat3 knockdown or dominant-negative Stat3 sensitized cells to inhibitors.
• Mutant amyloid precursor protein sensitized neuronal cells to Stat3 inhibitors.
• Primary neurons and astrocytes showed sensitivity similar to cancer cell lines.

Conclusions:

• Stat3 inhibitors affect both cancer and normal neural cells.
• Careful targeting of Stat3 inhibitors to GBM is necessary to avoid neurotoxicity.
• Potential neurotoxicity could lead to AD-like neuropsychiatric dysfunctions.